Detalhe da pesquisa
1.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Cancer
; 130(8): 1270-1280, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38153814
2.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Cancer
; 129(11): 1704-1713, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36932983
3.
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Cancer
; 128(13): 2449-2454, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363892
4.
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.
Blood
; 135(5): 381-386, 2020 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31869407
5.
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Cancer
; 127(15): 2657-2665, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794557
6.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Br J Haematol
; 193(2): 356-368, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33222197
7.
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.
Blood
; 134(12): 935-945, 2019 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31395600
8.
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.
Hematol Oncol
; 39(3): 409-418, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33590502
9.
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Cancer
; 126(6): 1243-1252, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31860137
10.
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
Hematol Oncol
; 38(3): 372-380, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32271957
11.
Second cancers in MPN: Survival analysis from an international study.
Am J Hematol
; 95(3): 295-301, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31816122
12.
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.
Hematol Oncol
; 37(4): 418-423, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30985017
13.
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.
Ann Hematol
; 98(4): 889-896, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30515542
14.
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.
Br J Haematol
; 183(1): 35-46, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30010187
15.
Comparison of JAK2V617F -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology.
Hematol Oncol
; 36(1): 269-275, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28509339
16.
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.
Hematol Oncol
; 36(1): 285-290, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28512865
17.
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.
Hematol Oncol
; 2018 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29624703
18.
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia.
Br J Haematol
; 176(2): 258-267, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27391055
19.
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.
Am J Hematol
; 92(1): 37-41, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27701770
20.
Cardiovascular events and intensity of treatment in polycythemia vera.
N Engl J Med
; 368(1): 22-33, 2013 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-23216616